Equity

BDBPX

iShares Russell 2000 Small-Cap Index Fund

  • NAV as of Nov 20, 2024 $26.35
    52 WK: 20.61 - 27.58
  • 1 Day NAV Change as of Nov 20, 2024 0.01 (0.04%)
  • NAV Total Return as of Nov 20, 2024 YTD: 15.69%

Overview

Investment Approach

Invests in a portfolio of assets whose performance seeks to match the performance of the Russell 2000® Index.
Loading

Performance

Performance

  1y 3y 5y 10y
Total Return (%) 26.27 1.56 9.07 8.50
Return w/ Sales Charge (%) 19.64 -0.25 7.90 7.91
Benchmark (%) 26.76 1.84 9.39 8.78
Morningstar Category Avg. (%) 30.63 2.36 9.39 7.88
Morningstar Ranking 222/588 480/566 378/543 -
Morningstar Quartile 2 4 3 3
Lipper Ranking 334/1013 824/970 643/915 -
Lipper Quartile 2 4 3 -
  YTD 1m 3m 1y 3y 5y 10y
Total Return (%) 10.82 0.64 9.14 26.27 4.76 54.37 126.06
Return w/ Sales Charge (%) 5.00 -4.65 3.42 19.64 -0.74 46.27 114.18
Benchmark (%) 11.17 0.70 9.27 26.76 5.64 56.61 132.10
Morningstar Category Avg. (%) 9.03 -1.79 -2.09 30.63 13.86 62.49 128.72
  2019 2020 2021 2022 2023
Total Return (%) 25.25 19.65 14.42 -20.57 16.62
Annual w/ Sales Charge (%) 18.68 13.37 8.41 -24.74 10.50
Benchmark (%) 25.52 19.96 14.82 -20.44 16.93
Morningstar Category Avg. (%) 23.75 10.99 24.19 -16.24 16.18

Performance is shown after deduction of ongoing charges. Any entry and exit charges are excluded from the calculation.

The performance quoted represents past performance and does not guarantee future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance quoted.
Click here for Distribution data

Key Facts

Key Facts

Net Assets
as of Nov 20, 2024
$315,267,298
Share Class launch date
Aug 06, 2018
Benchmark Index
Russell 2000 Index (Gross Total Return) (USD)
Morningstar Category
Small Blend
CUSIP
066923244
Open to New Investors
No
Net Assets of Fund
as of Nov 20, 2024
$2,957,333,286
Asset Class
Equity
Distribution Frequency
Annual
Lipper Classification
Small-Cap Core Funds
Max Offer Price
as of Nov 20, 2024
$27.81
Turnover Percent in the Annual Report
as of Dec 31, 2023
29%

Portfolio Characteristics

Portfolio Characteristics

Number of Holdings
as of -
-
P/B Ratio
as of Jun 30, 2023
0.00
Average Market Cap (Millions)
as of -
-
Fund Standard Deviation (3y)
as of Oct 31, 2024
22.42
Best 3-Month Return Over the Last 3 Years
3 months ending Jan 31, 2024
17.50%
P/E Ratio
as of Jun 30, 2023
0.00
Alpha (3y)
as of Oct 31, 2024
-0.02
R-Squared (3y)
as of Oct 31, 2024
100.00
Beta (3y)
as of Oct 31, 2024
1.00
Worst 3-Month Return Over the Last 3 Years
3 months ending Jun 30, 2022
-17.26%
This information must be preceded or accompanied by a current prospectus. For standardized performance, please see the Performance section above.

Fees

Fees

as of current prospectus
Gross Expense Ratio 0.38%
Net Expense Ratio 0.37%

Net Expense Ratio excluding Investment Related Expenses is 0.37%

  • Acquired Fund Fees and Expenses 0.00%
  • Interest expense 0.00%

Ratings

Ratings

Lipper Leader

 
 
 
Overall Lipper Leaders ratings based on an equal-weighted average of percentile ranks for each measure over 3-, 5-, and 10-year periods (if applicable) and do not take into account the effects of sales charges for these categories (Consistent Return, Preservation, Total Return, Expense, and Tax Efficiency) as of Oct 31, 2024 out of 970, 12,312, 970, 262 and 970 Funds, respectively in Lipper's Small-Cap Core Funds classification.

Holdings

Holdings

as of Sep 30, 2020
Name Weight (%)
PENN NATIONAL GAMING INC 0.58
SUNRUN INC 0.48
CAESARS ENTERTAINMENT INC 0.41
MYOKARDIA INC 0.37
NOVAVAX INC 0.35
Name Weight (%)
IRHYTHM TECHNOLOGIES INC 0.35
LHC GROUP INC 0.34
MIRATI THERAPEUTICS INC 0.33
CHURCHILL DOWNS INCORPORATED 0.33
MOMENTA PHARMACEUTICALS INC. 0.33
Name Market Value Weight (%) Quantity
Holdings are subject to change. Fund holdings and allocations shown are unaudited, and may not be representative of current or future investments. Holdings shown should not be deemed as a recommendation to buy or sell securities. The user relies on this data at its own risk and neither BlackRock nor any other party makes any representations or express or implied warranties (which are expressly disclaimed) nor shall they incur any liability for any errors or omissions in the data.

Exposure Breakdowns

Exposure Breakdowns

as of Sep 30, 2020

% of Market Value

Type Fund Benchmark Net
as of Sep 30, 2020

% of Market Value

Type Fund Benchmark Net
Negative weightings may result from specific circumstances (including timing differences between trade and settle dates of securities purchased by the funds) and/or the use of certain financial instruments, including derivatives, which may be used to gain or reduce market exposure and/or risk management.

Allocations are subject to change.

There are many ways to access BlackRock Funds, learn how you can add them to your portfolio
Learn More Learn More

Discuss with your financial planner today

Share this fund with your financial planner to find out how it can fit in your portfolio.

Buy through your brokerage

BlackRock funds are also available through certain brokerage accounts. Visit your brokerage today to see how you can get started.

Carefully consider the Funds' investment objectives, risk factors, and charges and expenses before investing. This and other information can be found in the Funds' prospectuses or, if available, the summary prospectuses, which may be obtained by visiting the iShares ETF and BlackRock Fund prospectus pages. Read the prospectus carefully before investing. Investing involves risk, including possible loss of principal.

The Funds are distributed by BlackRock Investments, LLC (together with its affiliates, “BlackRock”).

©2020 BlackRock, Inc. All rights reserved. BLACKROCK, BLACKROCK SOLUTIONS, BUILD ON BLACKROCK, ALADDIN, iSHARES, iBONDS, iTHINKING, iSHARES CONNECT, FUND FRENZY, LIFEPATH, SO WHAT DO I DO WITH MY MONEY, INVESTING FOR A NEW WORLD, BUILT FOR THESE TIMES, the iShares Core Graphic, CoRI and the CoRI logo are registered and unregistered trademarks of BlackRock, Inc., or its subsidiaries in the United States and elsewhere. All other marks are the property of their respective owners.

USR-9694

Portfolio Managers

Portfolio Managers

Paul Whitehead
Paul Whitehead
Read More

Paul Whitehead, Managing Director, is the Deputy Head of Index Equity Investments with responsibility for Global Index Asset Allocation, Transition Management (TRIM), and Americas Portfolio Management within BlackRock’s Global Markets & Index Investments (“BGM”).

 

Mr. Whitehead's service with the firm dates back to 1996, including his years with Barclays Global Investors (BGI), which merged with BlackRock in 2009. Prior to assuming his current role , Mr. Whitehead was Global Head of Equity Trading, Global Head of Transition Management and Head of Americas Equity Trading. Previously, he managed the trading team responsible for all Institutional Index funds, Exchange Traded funds, and Transition Management mandates.

 

Mr. Whitehead earned a BS degree in economics at the University of Colorado in 1993.

Jennifer Hsui
Jennifer Hsui
Read More

Jennifer Hsui, CFA, Managing Director, is Global Head of Index Equity Investments within BlackRock Global Markets & Index Investments ("BGM"). She leads the team responsible for delivering investment quality across roughly $5 trillion of BlackRock’s equity index funds and ETFs.

 

Ms. Hsui's service with the firm dates back to 2006, including her years with Barclays Global Investors (BGI), which merged with BlackRock in 2009. Prior to her current role, Ms. Hsui was CIO and co-Head of Index Equity, with responsibility for setting direction, establishing policy, and guiding investment decisions across Index Equity products. Prior to joining BGI, she worked as an equity research analyst covering the medical devices industry at RBC Capital Markets.

 

Ms. Hsui earned a BS degree in economics and biology from the University of California, Berkeley.

Portfolio Manager

Literature

Literature